How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

825 results for

Scleritis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Peripheral Ulcerative Keratitis Associated with Granulomatosis with Polyangiitis Emerging Despite Cyclophosphamide, Successfully Treated with Rituximab Full Text available with Trip Pro

Peripheral Ulcerative Keratitis Associated with Granulomatosis with Polyangiitis Emerging Despite Cyclophosphamide, Successfully Treated with Rituximab A 67-year-old Japanese man was diagnosed with granulomatosis with polyangiitis based on the presence of right maxillary sinusitis, proteinase 3 antineutrophil cytoplasmic antibody positivity, and right scleritis. A conjunctival biopsy specimen showed neutrophil-predominant infiltration around the vessels without granuloma. Because

2018 Internal Medicine

182. Sudden sensorineural hearing loss in atypical Cogan's syndrome: A case report Full Text available with Trip Pro

Sudden sensorineural hearing loss in atypical Cogan's syndrome: A case report The Cogan's syndrome (CS) is a very uncommon inflammatory condition that appears in young adults without a gender predisposition. It can be presented as typical, with interstitial non-syphilitic keratitis and Ménière-like audiovestibular manifestations. An atypical form of CS involves uveitis, scleritis, episcleritis, and systemic vascuitis symptoms. This is a case of a 41-year old male who reported eye redness

2018 Annals of Medicine and Surgery

183. Clinical Manifestations and Ophthalmic Outcomes of Ocular Syphilis at a Time of Re-Emergence of the Systemic Infection Full Text available with Trip Pro

for human immunodeficiency virus (HIV), 34.6% were positive. Ophthalmological evaluations included measurement of Snellen visual acuity and intraocular pressure, and assessment of inflammation by slit lamp examination and dilated posterior eye examination. Involvements in 214 eyes were anterior (6.1%), intermediate (8.4%), posterior (76.2%) and pan- (8.4%) uveitis, and scleritis (0.9%). Multiple anterior and posterior eye complications were observed, including cataract in the anterior eye (incidence

2018 Scientific reports

184. DRy Eye Outcome and Prescription Study

in at least one eye of at least 6/12. Exclusion Criteria: lacks capacity (e.g. dementia) poor understanding of English active other apparent ocular surface disease (including conjunctivitis, abrasion, recurrent erosion syndrome, episcleritis, inflamed pingueculum or pterygium, tumour, infectious keratitis). immune ocular pathology (including scleritis and uveitis). recent (within the last 3 months) or planned ocular surgery or intravitreal injections. current use of other ocular medication, e.g

2018 Clinical Trials

185. A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

(≤ Grade 2) not expected to resolve (such as neuropathy and alopecia) are exceptions and may enroll. Note: Subjects with a history of any grade immune-related ocular AE (e.g., episcleritis, scleritis, uveitis) will be excluded. Receipt of a live vaccine within 30 days of planned start of study therapy. Note: Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox/zoster, yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. Seasonal

2018 Clinical Trials

186. LSFG-SKIN, Laser Speckle Flowgraphy

normal and abnormal skin blood flow regionally in different areas of the body(face, extremities, over burns and wounds) at baseline and over time in response to treatment or environmental changes, such as temperature, light and pressure. Condition or disease Intervention/treatment Phase Hypertension Heart Failure Vascular Ischemia Burns Chemotherapy Effect Radiation Injuries Uveitis Scleritis Multiple Sclerosis Autonomic Neuropathy Stroke Intracranial Hemorrhages TIA Migraine Headache Pain Device (...) in and Exported from the U.S.: No Keywords provided by Randy Kardon, University of Iowa: perfusion inflammatory ischemia lesions neuropathy burns cancer stroke Additional relevant MeSH terms: Layout table for MeSH terms Heart Failure Multiple Sclerosis Hemorrhage Ischemia Headache Uveitis Intracranial Hemorrhages Scleritis Radiation Injuries Heart Diseases Cardiovascular Diseases Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System Nervous System Diseases Demyelinating Diseases

2018 Clinical Trials

187. Ocular Basidiobolomycosis: A Case Report Full Text available with Trip Pro

Ocular Basidiobolomycosis: A Case Report Ocular basidiobolomycosis is an unusual infection caused by fungus of the order Entomophthorales. This fungus has been previously reported as a common cause of skin, subcutaneous, and gastrointestinal tract infection. The fungus isolation and its typical characteristics are clues for diagnosis of this uncommon pathogen.A 47-year-old male patient with nodular scleritis in the left eye after an eye injury from sawdust was treated as bacterial scleritis (...) . The lesion improved with early surgical drainage and antibacterial therapy; then, he was discharged from the hospital. Thereafter, the patient was re-admitted due to progression of infectious scleritis with keratitis and orbital cellulitis. Surgical abscess drainage was performed again. The microbiological study demonstrated Basidiobolus ranarum. The patient was treated with topical ketoconazole, subconjunctival fluconazole injection, and oral itraconazole with partial response to the treatment. However

2018 Case reports in ophthalmology

188. Clinical outcomes of 4-point scleral fixated 1-piece hydrophobic acrylic equiconvex intraocular lens using polytetrafluoroethylene suture Full Text available with Trip Pro

%). There was one case of recurrent retinal detachment. One patient presented with an erosion of the Gore-Tex suture through the conjunctiva resulting in a purulent scleritis 6 months after the initial surgery, and was managed with removal of the IOL, debridement, and cryotherapy. Forty-one of 49 patients completed 3-month follow-up, among which visual acuity improved, deteriorated, or remained same compared to baseline in 27/49 (55.1%), 8/49 (16.3%), and 6/49 (12.2%) eyes, respectively.In the current study

2018 Clinical ophthalmology (Auckland, N.Z.)

189. Is this a worrisome red eye? Episcleritis in the primary care setting Full Text available with Trip Pro

onset of redness, lacrimation, and photophobia. The diagnosis of is essentially clinical, and eye pain or tenderness should raise the concern for scleritis. Ophthalmological referral is recommended to rule out scleritis. Bloodwork to diagnose associated systemic rheumatological disease may be helpful. Cold compresses and artificial tears provide symptomatic relief. Topical nonsteroidal anti-inflammatory drugs (NSAIDs) and steroids are used for persistent symptoms. Rarely, systemic steroids may

2018 Journal of community hospital internal medicine perspectives

190. Ocular Manifestations in Rheumatic Diseases

Description Go to Brief Summary: This is a search strategy for determining the prevalence of ocular complications in inflammatory rheumatic diseases for the purposes of a meta analysis. Condition or disease Intervention/treatment Uveitis Conjunctivitis Keratoconjunctivitis Sicca Xerophthalmia Eye Hemorrhage Optic Neuritis Papilledema Orbital Diseases Retinal Vein Occlusion Retinal Artery Occlusion Macular Edema Retinitis Chorioretinitis Iridocyclitis Scleritis Choroid Hemorrhage Blindness Amaurosis Fugax (...) Other: No intervention used Detailed Description: For the purposes of determining the prevalence of ocular complications in inflammatory rheumatic diseases, the following search terms were used: conjunctivitis, keratoconjunctivitis sicca, xerophthalmia, uveitis, eye hemorrhage, optic neuritis, papilledema, orbital disease, retinal artery/vein occlusion, macular edema, retinitis, chorioretinitis, scleritis, iridocyclitis, choroid hemorrhage, blindness and amaurosis fugax. These terms were searched

2018 Clinical Trials

191. Performance and Safety of the ARGOS-SC01 Suprachoroidal Pressure Sensor in Patients With Glaucoma Undergoing Non-penetrating Glaucoma Surgery

of severe active inflammatory eye diseases (i.e. uveitis, retinitis, scleritis) in one or both eyes within 6 months prior to ARGOS-SC implantation Ocular surgery procedure(s) (excluding selective laser trabeculoplasty and peripheral iridotomy) within 6 months (cataract surgery within 3 months) prior to ARGOS-SC implantation in the study eye that can affect the assessment of IOP by Goldmann Applanation tonometry Ocular disease other than glaucoma that may affect assessment of visual acuity and/or IOP

2018 Clinical Trials

192. Patch Grafting Using an Ologen Collagen Matrix to Manage Tubal Exposure in Glaucoma Tube Shunt Surgery Full Text available with Trip Pro

years after implantation, the tube was not exposed. Anterior-segment optical coherence tomography (AS-OCT) showed dense conjunctival tissue over the tube. Case 2 was an 82-year-old man with peripheral keratitis, anterior scleritis, and secondary glaucoma in the right eye who underwent tube shunt surgery using an Ahmed glaucoma valve and cataract surgery. Intraoperatively, scleritis-related scleral thinning prevented the tube from being covered fully by an autologous scleral flap. An ologen Collagen

2018 Case reports in ophthalmology

193. Tofacitinib for Inflammatory Eye Disease

University School of Medicine Study Details Study Description Go to Brief Summary: Non-infectious inflammatory eye disease, such as uveitis and scleritis, is a chronic, auto-immune process that leads to vision loss. While steroids are effective in the short term, the side-effect profile of chronic steroid use necessitates the identification of effective steroid-sparing therapies. Tofacitinib is a small molecule that inhibits the signaling pathways of multiple inflammatory cytokines. The investigators (...) plan to evaluate whether tofacitinib may have efficacy for patients with uveitis and / or scleritis. Condition or disease Intervention/treatment Phase Uveitis Scleritis Drug: tofacitinib Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 5 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Tofacitinib for the Treatment of Inflammatory Eye Disease

2018 Clinical Trials

194. Study of the Safety of USB005 in Healthy Volunteers

the past 3 months of screening visit in either eye; Current or chronic history of ocular infection (bacterial, viral or fungal) or corneal irritation within the past 3 months of screening visit in either eye OR ongoing or recurrent ocular inflammation (ie, moderate to severe blepharitis, allergic conjunctivitis, peripheral ulcerative keratitis, scleritis, uveitis) in either eye; Abnormal tearing, OR expected regular use of prescription or expected use of OTC tear substitutes within 4 weeks prior to Day

2018 Clinical Trials

195. Treatment of Macular Edema After Cataract Surgery With Subconjunctival Aflibercept

visits and study-related procedures Provide signed informed consent Exclusion Criteria: Retinal diseases (including diabetic retinopathy, retinal vein or artery occlusion, neovascular age-related macular degeneration, radiation retinopathy, vitreomacular traction, epiretinal membrane). Active intraocular inflammation (grade trace or above) in the study eye, or history of idiopathic or autoimmune-associated uveitis in either eye. Active infectious conjunctivitis, keratitis, scleritis

2018 Clinical Trials

196. MSC-Exos Promote Healing of MHs

not keep prone position. Secondary macular lesions The equivalent spherical diopter of the study eye before any refractive correction or cataract surgery, which is greater than 6.0d or above 26mm of the ocular axis of the study eye. Intraocular pressure is higher than 25mmHg Within ocular inflammation, such as eye blepharitis, scleritis, keratitis and conjunctivitis. Systemic condition is poor, such as the poor control of diabetes and hypertension, myocardial infarction, cerebrovascular accident, renal

2018 Clinical Trials

197. H-1337 Ophthalmic Solution Phase 1/2

in either eye. Unwillingness to be contact lens free during study participation. Any history of uveitis, keratitis, or scleritis in either eye. Any history of penetrating ocular trauma in either eye. History within 3 months prior to Screening Visit of clinically significant moderate or severe chronic or active blepharitis, ocular dermatitis, or recent ocular conjunctivitis and/or ocular inflammation in either eye. Mild blepharitis, hyperemia (due to prostaglandin use) and/or blepharitis, and/or mild

2018 Clinical Trials

198. Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept

- 4) in the study eye Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye Aphakia in the study eye Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg despite treatment with anti-glaucoma medication) Systemic Exclusion Criteria Use of systemic anti-VEGF medications within 6 months of screening visit History of cerebrovascular accident, myocardial infarction, ventricular arrhythmia, unstable angina, coronary or peripheral artery

2018 Clinical Trials

199. To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus

inflammation (grade trace or above) in either eye Any active infection (e.g. conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis) in either eye History of uveitis in either eye Structural damage within 1 disc diameter of the center of the macula in the study eye likely to preclude an improvement in visual acuity following the resolution of macular oedema, including (geographic) atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s), or organized hard exudates plaques

2018 Clinical Trials

200. Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)

. Cataract surgery within the previous 6 months in the study eye is excluded. Intraocular pressure (IOP) of >22 mmHg in the study eye or use of >2 antiglaucoma agents (combination agents count as 2 agents) in the study eye. Evidence of infectious dacrocystitis, significant blepharitis, active conjunctivitis, infectious keratitis, or scleritis in either eye, or any other condition that might affect the safety of the IVT injection. Current active proliferative diabetic retinopathy (PDR), active anterior

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>